专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006018418A3 ANTIANGIOGENIC PEPTIDES 审中-公开
标题翻译：抗血管生成肽
公开(公告)号：WO2006018418A3
公开(公告)日：2006-08-10
申请号：PCT/EP2005053952
申请日：2005-08-11
申请人： UNIV LIEGE , GEMBLOUX FACULTE UNIVERSITAIRE , MARTIAL JOSEPH , STRUMAN INGRID , NGUYEN NGOC-QUYNH-NHU , BRASSEUR ROBERT , LINS LAURENCE
发明人： MARTIAL JOSEPH , STRUMAN INGRID , NGUYEN NGOC-QUYNH-NHU , BRASSEUR ROBERT , LINS LAURENCE
IPC分类号： C07K14/61 , A61K38/16 , A61K38/22 , A61K38/39 , A61P43/00 , C07K14/155 , C07K14/47 , C07K14/575 , C07K14/78
CPC分类号： C07K14/005 , A61K38/00 , C07K14/47 , C07K14/4711 , C07K14/57518 , C07K14/57554 , C07K14/61 , C07K14/78 , C12N2740/15022
摘要： The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, lle, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: lle, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, lle, Val; X7 is an amino acid residue of: Leu, lle, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, lle, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.
摘要翻译：本发明涉及包含分离的抗血管生成肽或包含抗血管生成肽的重组蛋白的药物组合物，其中所述肽的长度在11至40个氨基酸之间并且具有抗血管生成活性，所述肽包含氨基酸序列：X1-X2 -X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14，其中X1是与形成螺旋相容的任何氨基酸残基; X2是以下氨基酸残基：Leu，Ile，Val; X3是Arg，Lys，His，Ser，Thr的氨基酸残基; X4是Ile，Leu，Val的氨基酸残基; X5是与形成螺旋相容的任何氨基酸残基; X6是Leu，Ile，Val的氨基酸残基; X7是Leu，Ile，Val，Ser，Thr的氨基酸残基; X8是与形成螺旋相容的任何氨基酸残基; X9是与形成螺旋相容的任何氨基酸残基; X10是Gln，Glu，Asp，Arg，His，Lys，Asn的氨基酸残基; X11是Ser，Thr的氨基酸残基; X12是Trp，Tyr，Phe的氨基酸残基; X13是Leu，Ile，Val，Asn，Gln的氨基酸残基; X14是Glu，Gln，Asp，Asn的氨基酸残基。

2. 发明申请

WO2011101373A1 A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF THROMBOSIS-RELATED DISEASES COMPRISING A FRAGMENT OF PROLACTIN (PRL)-GROWTH HORMONE (GH)-PLACENTAL LACTOGEN (PL)-FAMILY PROTEIN 审中-公开
标题翻译：用于治疗包含丙泊酚（PRL） - 生长激素（GH） - 原位乳酸（PL） - 蛋白质蛋白的片段的相关性疾病的药物组合物
公开(公告)号：WO2011101373A1
公开(公告)日：2011-08-25
申请号：PCT/EP2011/052293
申请日：2011-02-16
申请人： UNIVERSITÉ DE LIÈGE , STRUMAN, Ingrid , MARTIAL, Joseph , BAJOU, Khalid , D'AMICO, Salvino
发明人： STRUMAN, Ingrid , MARTIAL, Joseph , BAJOU, Khalid , D'AMICO, Salvino
IPC分类号： A61K38/22 , A61K38/27 , A61P9/10
CPC分类号： A61K38/2257 , A61K38/22 , A61K38/27
摘要： The present invention refers to a pharmaceutical composition for use in the preventive and/or therapeutic treatment of thrombosis-related diseases or conditions relating to high level of PAI-1 expression, which composition is comprising A) a fragment of a polypeptide or protein of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family and homologous derivatives thereof, which fragment comprises from 6 to 14 consecutive amino acid residues of the amino acid sequence having the following general formula (I): X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11 -X12-X13-X14 (SEQ ID NO: 11), wherein X1 is an amino acid residue of : Leu, Phe; X2 is an amino acid residue of : Leu; X3 is an amino acid residue of : Arg, Ser; X4 is an amino acid residue of : Ile, Leu; X5 is an amino acid residue of : Ser, Ile; X6 is an amino acid residue of : Leu, VaI; X7 is an amino acid residue of : Leu, Ser, X8 is an amino acid residue of : Leu, lIe X9 is an amino acid residue of : Ile, Leu; X10 is an amino acid residue of : GIn, GIu, Arg; II 1 is an amino acid residue of : Ser; X12 is an amino acid residue of : Trp; X13 is an amino acid residue of : Leu, Asn; X14 is an amino acid residue of : GIu; or B) a peptide or a recombinant protein comprising said peptide, wherein the peptide is from 6 to 50 amino acids in length and has the activity to inhibit plasminogen activator inhibitor I (PAI-1 ), said peptide comprising from 6 to 14 consecutive amino acid residues of the amino acid sequence of said general formula (I); or C) a polynucleotide encoding said fragment of a polypeptide or protein of A) or said peptide or recombinant protein of B).
摘要翻译：本发明涉及用于预防和/或治疗血栓形成相关疾病或与高水平PAI-1表达有关的病症的药物组合物，该组合物包含A）多肽或催乳素蛋白的片段（PRL）生长激素（GH） - 胎盘催乳素（PL）家族及其同源衍生物，该片段包含具有以下通式（I）的氨基酸序列的6至14个连续氨基酸残基：X1-X2 -X3-X4-X5-X6-X7-X8-X9-X10-X11 -X12-X13-X14（SEQ ID NO：11），其中X1是氨基酸残基：Leu，Phe; X2是氨基酸残基：Leu; X3是氨基酸残基：Arg，Ser; X4是以下氨基酸残基：Ile，Leu; X5是以下氨基酸残基：Ser，Ile; X6是以下氨基酸残基：Leu，Val; X7是以下氨基酸残基：Leu，Ser，X8是Leu的氨基酸残基，I X9是Ile，Leu的氨基酸残基; X10是以下氨基酸残基：Gln，Glu，Arg; II 1是以下氨基酸残基：Ser; X12是以下氨基酸残基：Trp; X13是以下氨基酸残基：Leu，Asn; X14是以下氨基酸残基：Glu; 或B）包含所述肽的肽或重组蛋白，其中所述肽的长度为6至50个氨基酸并且具有抑制纤溶酶原激活物抑制剂I（PAI-1）的活性，所述肽包含6至14个连续氨基所述通式（I）的氨基酸序列的酸残基; 或C）编码A）或B）的多肽或蛋白质的所述肽或重组蛋白的所述片段的多核苷酸。

3. 发明申请

WO2006018418A2 ANTIANGIOGENIC PEPTIDES 审中-公开
标题翻译：抗生素
公开(公告)号：WO2006018418A2
公开(公告)日：2006-02-23
申请号：PCT/EP2005/053952
申请日：2005-08-11
申请人： UNIVERSITÉ DE LIÈGE , FACULTÉ UNIVERSITAIRE DES SCIENCES AGRONOMIQUES DE GEMBLOUX , MARTIAL, Joseph , STRUMAN, Ingrid , NGUYEN, Ngoc-Quynh-Nhu , BRASSEUR, Robert , LINS, Laurence
发明人： MARTIAL, Joseph , STRUMAN, Ingrid , NGUYEN, Ngoc-Quynh-Nhu , BRASSEUR, Robert , LINS, Laurence
IPC分类号： C07K14/61 , C07K14/575 , C07K14/78 , C07K14/47 , C07K14/155 , A61K38/22 , A61K38/39 , A61K38/16 , A61P43/00
CPC分类号： C07K14/005 , A61K38/00 , C07K14/47 , C07K14/4711 , C07K14/57518 , C07K14/57554 , C07K14/61 , C07K14/78 , C12N2740/15022
摘要： The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, lle, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: lle, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, lle, Val; X7 is an amino acid residue of: Leu, lle, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, lle, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.
摘要翻译：本发明涉及包含分离的抗血管生成肽或包含抗血管生成肽的重组蛋白质的药物组合物，其中所述肽的长度为11至40个氨基酸且具有抗血管生成活性，所述肽包含氨基酸序列：X1-X2 -X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14，其中X1是与形成螺旋相容的任何氨基酸残基; X2是氨基酸残基：Leu，lle，Val; X3是氨基酸残基：Arg，Lys，His，Ser，Thr; X4是以下氨基酸残基：lle，Leu，Val; X5是与形成螺旋相容的任何氨基酸残基; X6是以下氨基酸残基：Leu，lle，Val; X7是Leu，Ile，Val，Ser，Thr的氨基酸残基; X8是与形成螺旋相容的任何氨基酸残基; X9是与形成螺旋相容的任何氨基酸残基; X10是以下氨基酸残基：Gln，Glu，Asp，Arg，His，Lys，Asn; X11是以下氨基酸残基：Ser，Thr; X12是以下氨基酸残基：Trp，Tyr，Phe; X13是Leu，Ile，Val，Asn，Gln的氨基酸残基; X14是Glu，Gln，Asp，Asn的氨基酸残基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式